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Abstract 34 
The aim of this paper is to present the first study on spatial and temporal variation in the 35 
enantiomeric profile of chiral drugs in eight European cities. Wastewater-based epidemiology 36 
(WBE) and enantioselective analysis were combined to evaluate trends in illicit drug use in the 37 
context of their consumption vs direct disposal as well as their synthetic production routes. 38 
Spatial variations in amphetamine loads were observed with higher use in Northern European 39 
cities. Enantioselective analysis showed a general enrichment of amphetamine with the R-(-)-40 
enantiomer in wastewater indicating its abuse. High loads of racemic methamphetamine were 41 
detected in Oslo (EF = 0.49 ± 0.02). This is in contrast to other European cities where S-(+)-42 
methamphetamine was the predominant enantiomer. This indicates different methods of 43 
methamphetamine synthesis and/or trafficking routes in Oslo, compared with the other cities 44 
tested. An enrichment of MDMA with the R-(-)-enantiomer was observed in European 45 
wastewaters indicating MDMA consumption rather than disposal of unused drug. MDA’s chiral 46 
signature indicated its enrichment with the S-(+)-enantiomer, which confirms its origin from 47 
MDMA metabolism in humans. HMMA was also detected at quantifiable concentrations in 48 
wastewater and was found to be a suitable biomarker for MDMA consumption. Mephedrone 49 
was only detected in wastewater from the United Kingdom with population-normalised loads 50 
up to 47.7 mg 1000 people-1 day-1. The enrichment of mephedrone in the R-(+)-enantiomer in 51 
wastewater suggests stereoselective metabolism in humans, hence consumption, rather than 52 
3 
direct disposal of the drug. The investigation of drug precursors, such as ephedrine, showed that 53 
their presence was reasonably ascribed to their medical use. 54 
55 
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1. Introduction59 
Since the first study by Zuccato et al. (Zuccato, Chiabrando et al. 2005), where wastewater-60 
based epidemiology (WBE) was introduced as an approach to estimate community-wide illicit 61 
drug use trends, WBE has proven to provide valuable and complementary information to 62 
traditional epidemiological approaches (Thomas and Reid 2011, Kasprzyk-Hordern, Bijlsma et 63 
al. 2014). Indeed, the analysis of carefully selected biomarkers, which are often unique human 64 
urinary metabolic excretion products, has allowed for near real-time profiling of the 65 
community-wide use of a number of illicit drugs (Thomas, Bijlsma et al. 2012, Ort, van Nuijs 66 
et al. 2014), new psychoactive substances (NPS) (Reid, Derry et al. 2014, Castiglioni, Borsotti 67 
et al. 2015), alcohol (Reid, Langford et al. 2011) and tobacco (Castiglioni, Senta et al. 2014) 68 
use and counterfeit medicines (Causanilles, Emke et al. 2016). The study by Zuccato et al. was 69 
followed and further developed by other research groups (Van Nuijs, Pecceu et al. 2009, van 70 
Nuijs, Pecceu et al. 2009, Karolak, Nefau et al. 2010, Metcalfe, Tindale et al. 2010, Terzic, 71 
Senta et al. 2010, Reid, Langford et al. 2011, van Nuijs, Castiglioni et al. 2011). The first 72 
Europe-wide study in 2011, led by the SCORE group (www.score-cost.eu), involved 19 cities 73 
and estimated temporal and spatial drugs use trends across Europe (Thomas, Bijlsma et al. 74 
2012). This was followed by Europe-wide monitoring of 23 cities in 2012 (Ort, van Nuijs et al. 75 
2014) and then 42 cities in 2013 (http://www.emcdda.europa.eu/topics/pods/waste-water-76 
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analysis 2016). WBE is currently used to report on world-wide illicit drug use trends (Lai, 77 
O'Brien et al. 2016, Tscharke, Chen et al. 2016) and feeds into the Europe-wide evidence based 78 
early warning system managed by the European Monitoring Centre for Drugs & Drug 79 
Addiction (EMCDDA) (http://www.emcdda.europa.eu/activities/wastewater-analysis) 80 
(http://www.emcdda.europa.eu/activities/wastewater-analysis).  81 
There are several key stages that need to be considered when developing new WBE 82 
applications: (i) biomarker selection; (ii) collection of representative wastewater samples; (iii) 83 
measurement of biomarkers in wastewater; (iv) calculation of population-normalised mass 84 
loads and, finally, (v) estimation of the consumption pro capita. Biomarker selection is 85 
considered to be of critical importance. This cannot be limited to the parent drug itself if the 86 
determination of drug consumption estimate is the aim, since bias related to disposal of the 87 
unused drug might take place. A biomarker should be uniquely formed in the body, be stable 88 
and present in wastewater at quantifiable concentrations. Furthermore, the impact of 89 
transformation of biomarkers in sewer biofilm/suspended solids between the discharge and the 90 
sampling points should be considered as it could affect the detected amount of the analytes, 91 
thereby influencing epidemiological observations (McCall, Scheidegger et al. 2016, Ramin, 92 
Libonati Brock et al. 2016). Unfortunately, as it is not always possible to select a unique 93 
metabolic biomarker, different solutions need to be sought. One of the innovative approaches 94 
focuses on enantiomerism of chiral drugs and their stereoselective human metabolism [26]. 95 
Enantiomeric profiling can complement WBE data with valuable information on abuse trends 96 
and potency of chiral drugs. It can also help with distinguishing between the legal and illicit use 97 
of drugs, as well as providing an indication of actual consumption as opposed to disposal of 98 
non-consumed drugs [2]. This is because drug synthesis is associated with different chiral 99 
signatures that depend on the routes of synthesis. Furthermore, chiral drugs undergo 100 
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stereoselective disposition in humans leading to changes in their chiral signature (expressed as 101 
enantiomeric fraction, EF) (Kasprzyk-Hordern 2010) when excreted. 102 
The potential of enantioselective analysis for WBE purposes has thus far only been 103 
demonstrated in a few limited studies focussing on (i) verification of the fate of chiral drugs 104 
during wastewater treatment and in the environment (Camacho-Muñoz 2015), (ii) confirmation 105 
of origin of amphetamine found in wastewater in the United Kingdom (UK) (Kasprzyk-Hordern 106 
and Baker 2012) and (iii) confirmation of MDA present in wastewater as a result of MDMA 107 
consumption rather than MDA use (Kasprzyk-Hordern and Baker 2012). Vázquez-Roig et al. 108 
(Vazquez-Roig, Kasprzyk-Hordern et al. 2014) reported usage patterns of chiral drugs in the 109 
catchment area of Valencia (Spain), by linking selective enrichment of MDMA with the R-(-)-110 
enantiomer in wastewater to human consumption. Enantioselective analysis also proved 111 
invaluable in establishing that the unexpectedly high quantity of MDMA detected during a 112 
monitoring campaign in 2011 in Utrecht was due to direct disposal of unused MDMA as a 113 
consequence of a police raid at a nearby illegal production facility (Emke, Evans et al. 2014) 114 
and not as a result of high levels of consumption. Similarly, Petrie et al. (Petrie, Youdan et al. 115 
2016) linked high levels of fluoxetine in wastewater with the disposal of the unused drug rather 116 
than its consumption. Recently, Castrignanò et al. (Castrignanò, Lubben et al. 2016) found 117 
mephedrone enriched with R-(+)-enantiomer in wastewater in the UK suggesting human use. 118 
Despite these findings, a limited number of studies have correlated the enantiomeric 119 
composition of chiral biomarkers to official statistics (Camacho-Muñoz 2015). Hence, this is 120 
the first pan-European study aimed at investigating enantiomeric profiling of “common” drugs 121 
of abuse, NPS and chiral drug precursors in eight cities from different countries with a total 122 
population equivalent of 4.9 million. The focus of this research was to: 123 
 quantify selected drugs in wastewater from eight European cities,124 
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 verify if drug residues in wastewater originated from the direct disposal of unused drugs 125 
into the sewer system or their consumption.,126 
127 
128 
2. Experimental129 
2.1.Chemicals and materials 130 
The following chiral analytes were selected in this study (Figure S1): (±)-mephedrone, (±)-4-131 
hydroxy-3-methoxymethamphetamine (HMMA), (±)-3,4-methylenedioxymethamphetamine 132 
(MDMA), (±)-4-hydroxy-3-methoxyamphetamine (HMA), (±)-methamphetamine, (±)-133 
amphetamine, (±)-3,4-methylenedioxyamphetamine (MDA), (±)-3,4-methylenedioxy-N-ethyl-134 
amphetamine (MDEA), (±)-ephedrine, (±)-pseudoephedrine, (±)-para-methoxyamphetamine 135 
(PMA), (±)-norephedrine. Table S1 shows properties of all analytes. Amphetamine-D5, 136 
methamphetamine-D5, mephedrone-D3, MDA-D5, MDMA-D5, MDEA-D5 and 1S,2R-(+)-137 
ephedrine-D3 were used as internal standards (ISs). 138 
All standards and ISs were of the highest purity available (>97%). Stock and working solutions 139 
of standards were stored at -20 °C. Methanol, acetonitrile and ammonium acetate were 140 
purchased from Sigma Aldrich, UK. Ultrapure water was obtained from MilliQ system (UK). 141 
Deactivation of the glassware was carried out as described in (Castrignanò, Lubben et al. 2016) 142 
to prevent the adsorption of basic analytes to the hydroxyl sites on the glass surface. 143 
2.2.Sample collection, storage and sample preparation 144 
24-hour composite wastewater influent samples were collected over seven consecutive days in145 
March 2015 from wastewater treatment plants (WWTPs) across Europe using best practice 146 
sampling protocol (Castiglioni, Thomas et al. 2014). The week in March was chosen as a 147 
“routine week”, in which no national and local festivities were taking place. Sampling sites 148 
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were in Norway (Oslo), United Kingdom (Bristol), Denmark (Copenhagen), The Netherlands 149 
(Utrecht), Belgium (Brussels), Switzerland (Zurich), Italy (Milan) and Spain (Castellón). Table 150 
S2 provides information on population and flow for the selected cities in the study. After 151 
collection, samples were transported to the local laboratory in refrigerated conditions and 152 
shipped on ice blocks to the UK within 24 hours. A fully validated analytical method was used 153 
for the detection and quantification of chiral drugs of abuse in wastewater as described 154 
elsewhere (Castrignanò, Lubben et al. 2016). 155 
2.3.Sample analysis 156 
Samples were analysed in triplicate using enantioselective high performance liquid 157 
chromatography coupled with tandem mass spectrometry system. Separation of all chiral 158 
analytes was undertaken with a CHIRALPAK® CBH HPLC column 5 μm particle size, L × I.D. 159 
10 cm × 2.0 mm with a chiral-CBH guard column 10 × 2.0 mm, 5 μm particle size (Chiral 160 
Technologies, France) using a Waters ACQUITY UPLC® system (Waters, Manchester, UK) 161 
under isocratic conditions at a 0.1 mL min-1. The mobile phase was a solution 1 mM ammonium 162 
acetate/methanol 85:15 v/v. The temperature was kept at 4 °C in the ACQUITY UPLCTM163 
autosampler, whilst at 25 °C in the column compartment. The injection volume was set at 20 164 
µL. 165 
A triple quadrupole mass spectrometer (Xevo TQD, Waters, Manchester, UK) equipped with 166 
an electrospray ionisation source was used in positive mode operating in the multiple reaction 167 
monitoring (MRM) mode. Table S3 shows MRM transitions used for selected analytes. 168 
MassLynx 4.1 (Waters, UK) was used to control the Waters ACQUITY system and the Xevo 169 
TQD. Data processing was carried out using TargetLynx software (Waters, Manchester, UK). 170 
Method validation data are provided in Tables S4-S8. 171 
2.4.Calculations 172 
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Enantiomeric fraction (EF) was calculated using the following equation (1): 173 
 
    

EF (1) 174 
where (+) is the concentration of (+)-enantiomer or the first eluted enantiomer and (-) is the 175 
concentration of (-)-enantiomer or the second eluted enantiomer. EF equals 0.5 in the case of a 176 
racemate, whilst 1 or 0 in the case of the enantiopure compound. 177 
In order to obtain daily mass loads, the concentrations of analytes expressed in ng L-1 (see Table 178 
S9) were multiplied by the flow rate (L day-1) and then normalised by the population size of the 179 
catchment area. This was essential for comparing data coming from different cities involved in 180 
the study.  181 
All relevant information on the selected chiral illicit drugs is gathered in Table S9S10. It 182 
includes: biomarkers used as drug target residue (DTR), urinary excretion data, correction 183 
factors (CFs) used for WBE estimates, EF expected in urine after human metabolism (EFurine), 184 
EF calculated from illegal synthesis of the drug (EFillegal_synth), information derived from the 185 
legal use of the drug with EF derived from the legal use of the drug (EFlegal source) and 186 
consumption estimates from official health statistics and from wastewater analysis. CF was 187 
calculated as the ratio between the molar ratio of the drug and its DTR and the urinary excretion 188 
data.  189 
Estimated community-wide consumptions were calculated using population-normalised mass 190 
loads and CF. 191 
192 
3. Results and Discussion193 
3.1.Amphetamines 194 
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Data on amphetamines consumption, reported by the European drug report 2015 (as a sum of 195 
amphetamine and methamphetamine), showed that 1.3 million Europeans within the ages of 15 196 
- 34 used amphetamines in the last year (EMCDDA 2015). This data was obtained using the197 
EMCDDA’s five key epidemiological indicators, which consist of “estimates of recreational 198 
use (based mainly on surveys), estimates of high-risk use, drug-related deaths, infectious 199 
diseases and drug treatment entry” along with Reitox focal points and other sources (EMCDDA 200 
2015). In this work, we applied WBE to estimate amphetamine and methamphetamine use in 201 
eight European cities. Unfortunately, no metabolic biomarkers of amphetamine and 202 
methamphetamine are validated for a reliable estimation of their abuse via WBE. Therefore, 203 
amphetamine and methamphetamine themselves are commonly used as biomarkers. This 204 
constitutes a problem since the analysis of parent drugs does not allow for distinguishing 205 
between consumed and unconsumed (meth)amphetamine. Additionally, amphetamine is also a 206 
metabolite of other (prescription) drugs, such as fenethylline, fenproporex, methamphetamine 207 
(Baselt) and selegiline (Ort, van Nuijs et al. 2014). Furthermore, the percentage of the 208 
unchanged amphetamine fraction in urine can change due to changes in urine pH (Table 209 
S9S10), leading to high uncertainty of calculations and possible over or underestimation of 210 
amphetamine use. The awareness of this uncertainty is well recognised in the scientific 211 
community studying amphetamine use using WBE (Chiaia-Hernandez, Banta-Green et al. 212 
2011), (Kasprzyk-Hordern, Dinsdale et al. 2009), (Postigo, Lopez de Alda et al. 2010), (van 213 
Nuijs, Mougel et al. 2011). As reported by Ort et al. (Ort, van Nuijs et al. 2014), the estimation 214 
of the amphetamine consumption has to be carried out in the context of methamphetamine data 215 
to distinguish between drug consumption from its metabolism. However, verification of the 216 
amphetamine/methamphetamine ratio cannot provide comprehensive information on drug 217 
consumption against direct disposal of unused drug. Additional evidence is therefore needed to 218 
distinguish between amphetamine abuse from its direct disposal or its usage as a prescription 219 
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drug. The phenomenon of enantiomerism of amphetamines may provide invaluable insight (see 220 
section S1-2 for further information). 221 
3.1.1. Amphetamine 222 
223 
224 
225 
226 
227 
228 
229 
230 
231 
232 
233 
234 
235 
236 
237 
238 
239 
240 
241 
Population-normalised amphetamine loads                                                     were <5 mg day-1 
1000 people-1 in Milan to a maximum weekly average value of 122.3 mg day-1 1000 people-1 
in Oslo, which shows higher amphetamine prevalence in Northern Europe (Figures 1a and 
S2, estimated consumptions also shown in Table S10S11). There was a decreasing 
amphetamine usage from Northern to Southern cities with only Italian and Spanish cities 
notably below the overall mean load of 28 mg day-1 1000 people-1 reported in the 2013 
European study (Ort, van Nuijs et al. 2014). By looking at the results from previous 
monitoring studies undertaken since 2012 (Ort, van Nuijs et al. 2014), temporal trends show 
that amphetamine loads increased in Oslo, Copenhagen, Brussels and Milan, even if they 
are very low for the latter city. They remained stable in Bristol and decreased in Zurich and 
in Utrecht. 
Enantiomeric profiling revealed that amphetamine in wastewater was enriched with the R-(-)-
enantiomer in most European cities (EFww<0.5, EF determined in the wastewater is referred as 
EFww;) the enrichment was significant as the unpaired t-test showed “t Stat > t Critical one-
tail” 8.25 > 1.81 for α = 0.05 and 8.25 > 4.14 for α = 0.001, p one-tail 0.0000045 < 0.001). 
This could indicate the consumption of racemic amphetamine (see section S1 for further 
discussion). Interestingly, amphetamine was found to be enriched with S-(+)-enantiomer in 
Milan (EFww=0.67±0.16). This suggests either usage of S-(+)-amphetamine (prescribed or 
illicit) or its formation as a result of metabolism of methamphetamine. Indeed, the illicit origin 
of amphetamine is very likely as methamphetamine was also found to be enriched with the S-
(+)-enantiomer (see section 3.1.2). 
242 
3.1.2. Methamphetamine 243 
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In this study, population-normalised methamphetamine loads ranged from <MQL in 244 
wastewater from Utrecht and Castellón  were <5 mg day-1 1000 people-1 in Bristol and Brussels 245 
to a maximum value of 172.4 mg day-1 1000 people-1 in Oslo wastewater (Figures 1b and S2, 246 
estimated consumptions in Table S11S12). According to the EMCDDA (EMCDDA 2015), high 247 
methamphetamine seizures were reported in Norway. A correlation (not statistically significant) 248 
was found between amount seized and loads in wastewater (Baz-Lomba, Salvatore et al. 2016). 249 
Zurich wastewater was found to have the second highest methamphetamine loads of 20.2 mg 250 
day-1 1000 people-1 as a weekly average of eight cities. Estimates in Copenhagen and Brussels 251 
were below the overall mean value. Wastewater from other European cities contained low 252 
levels. Despite being below the European average 253 
(http://www.emcdda.europa.eu/topics/pods/waste-water-analysis 2016), data from Milan has 254 
shown that the methamphetamine load has doubled when compared to data from the same area 255 
in 2013-14 and reaching 2012 loads. 256 
Enantiomeric profiling of European wastewater revealed that methamphetamine used in most 257 
European locations tested was the enantiopure S-(+)-methamphetamine with EFww ranging 258 
from 0.89±0.01 to 1.00±0.00. Norwegian wastewaters were an exception as they contained 259 
racemic methamphetamine (EFww(n=7)=0.49±0.02), which also indicated direct disposal of 260 
unused (±)-methamphetamine. Indeed, it has been reported by the EMCDDA (EMCDDA 2014) 261 
that methamphetamine available in Norway (and in Sweden) is mainly produced from 262 
phenylacetone and trafficked as racemate from Lithuania (see section S2 for further 263 
information). This is because clandestine production facilities in Lithuania tend to utilise a 264 
different synthetic route for methamphetamine production than facilities in Central Europe. 265 
Interestingly, since S-(+)-methamphetamine is the most potent psychotropic enantiomer 266 
(Freeman and Alder 2002) of methamphetamine, one can conclude that despite the lower usage 267 
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of methamphetamine in Zurich, Copenhagen, Brussels and Milan, the potency of the drug is 268 
much higher in these cities than in Oslo. 269 
3.2.MDMA and MDA 270 
The European drug report 2015 stated that 1.8 million Europeans with an age range from 15 271 
and 34 used ecstasy (with MDMA as the main ingredient) in the last year, with a low and stable 272 
prevalence trend (EMCDDA 2015). Europe-wide MDMA usage was also estimated using WBE 273 
(Thomas, Bijlsma et al. 2012, Ort, van Nuijs et al. 2014). Unfortunately, so far estimations are 274 
based on quantification of MDMA as a DTR in wastewater. Such an approach does not allow 275 
for accurate evaluation of MDMA consumption against the direct disposal of unused drug. 276 
There are two possible solutions: (1) specific metabolic biomarkers should be sought as MDMA 277 
is known to metabolise to MDA, DHMA and HMMA (Figure S3) (Castrignanò, Lubben et al. 278 
2016, Gonzalez-Marino, Zuccato et al. 2017), and (2) enantiomeric profiling should be 279 
implemented as MDMA undergoes stereoselective metabolism leading to the formation of 280 
chiral metabolites (see section S3 for further information). 281 
In the current study, population-normalised MDMA loads ranged from a minimum average 282 
value of 3.2 mg day-1 1000 people-1 in Castellón to a maximum value of 62.0 mg day-1 1000 283 
people-1 in Utrecht (Figures 2 and S2, estimated consumptions also in Table S12S13). 284 
Increasing MDMA loads were found during the weekend in all the countries involved, with the 285 
exception of Utrecht that had also high MDMA loads on a weekday. The overall MDMA 286 
weekly mean in 2013 was 18 mg day-1 1000 people-1 (Ort, van Nuijs et al. 2014). A geographical 287 
trend of MDMA loads from North to South was also found. Indeed, Northern European cities 288 
(except for Brussels) were mostly above the average. Enantiomeric profiling revealed that 289 
MDMA in wastewater is enriched with R-(-)-MDMA (0.32<EFww<0.40). This indicates that 290 
MDMA retrieved in wastewater comes from consumption, due to the stereoselective 291 
metabolism of MDMA in humans. Figure S3 shows expected EFwws in wastewater for MDMA 292 
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consumption using the conditions reported in Castrignanò et al (Castrignanò, Lubben et al. 293 
2016). Although illicit MDMA production sites are presumably mainly located in The 294 
Netherlands and Belgium (as mentioned in the EMCDDA report (EMCDDA 2015)), MDMA 295 
loads in Utrecht and Brussels were linked to human consumption rather than its direct disposal. 296 
In contrast, incidental findings in the wastewater of the cities city of Utrecht (Emke, Evans et 297 
al. 2014)[24] and Eindhoven [5] have shown that aberrantly high loads of (±)-MDMA can occur 298 
and can be ascribed to disposal of the unconsumed drug. 299 
The hypothesis that MDMA was present in European wastewaters as a result of its consumption 300 
was further evidenced by the study of MDA and its chiral signature. MDA can be a drug of 301 
abuse itself or a metabolite of MDMA and MDEA (3,4-methylenedioxyethylamphetamine). It 302 
is therefore of utmost importance to verify the origin of MDA. It does not have any medical 303 
applications and is available on the illicit market as a racemate (Karch and Drummer 2001) 304 
(EFillegal_synth=0.5). This is due to its non-stereoselective synthetic route. Similarly to MDMA, 305 
MDA’s metabolism favours the S-(+)-enantiomer (Meyer, Peters et al. 2009). Therefore, if 306 
MDA is consumed, it will be excreted in urine enriched with the R-(-)-enantiomer (EFurine<0.5). 307 
However, if MDA is formed as a result of the metabolism of MDMA or MDEA, it will be 308 
present in urine (and in wastewater) enriched with S-(+)-enantiomer (Levine 2003, Kasprzyk-309 
Hordern, Kondakal et al. 2010) (EFurine>0.5). In this study, MDEA, for which a new CF was 310 
proposed, was not detected in any European location. The highest loads of MDA were recorded 311 
in Utrecht with 3.2 mg day-1 1000 people-1, followed by Bristol with 1.9 mg day-1 1000 people-312 
1 and Oslo with 0.5 mg day-1 1000 people-1 at average weekly loads (Table S13S14). 313 
Interestingly, these countries have also high MDMA use, which led us to the conclusion that 314 
MDA could be present in wastewater due to consumption of MDMA. In most cases, MDA was 315 
found in wastewater enriched with S-(+)-enantiomer proving that its presence was associated 316 
with the consumption of MDMA, with exception of three days in Bristol, one day in Oslo and 317 
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in Utrecht when MDA was enriched of the R-(-)-form. This could indeed indicate an abuse of 318 
MDA. In the case of racemic MDA found in Utrecht for two days, this could indicate a 319 
combination of either the consumption of MDA and MDMA (most likely as HMMA data 320 
confirmed it) or simply the direct disposal of non-consumed MDA. 321 
As MDA is a minor and not exclusive metabolite of MDMA, other metabolites were also 322 
considered as possible DTRs for MDMA consumption: HMA and HMMA. HMA was detected 323 
at 3.4 mg day-1 1000 people-1 as weekly average in three days of the monitoring week in the 324 
Dutch city (Saturday, Sunday and Monday) and at 7.4 mg day-1 1000 people-1 in two days in 325 
Bristol samples (Sunday and Monday) (Table S14S15). Because of the low percentage of 326 
excretion of HMA after a dose of MDMA, its choice as MDMA DTR could be considered only 327 
in the case of high MDMA intake. Indeed, it was only found in those countries reporting the 328 
highest levels of MDMA. EFww showed values close to 0.5 when high HMA loads were 329 
detected. However, the relevance of enantioselective analysis is difficult to comment on 330 
because of the low number of positive samples for HMA. 331 
HMMA, on the other hand, was found in wastewater at ng/L level in six cities (i.e. no HMMA 332 
was detected in Oslo and Milan) (Table S15S16). HMMA’s excretion is 20%, which indicates 333 
that it could be used as MDMA’s DTR. Due to the stereoselective metabolism of MDMA, 334 
HMMA and its glucuronide derivative are formed enriched with S-(+)-enantiomer. 335 
Interestingly, HMMA sulphate is formed via non-stereoselective route (Schwaninger, Meyer et 336 
al. 2012). In this study, HMMA was enriched with the second eluting enantiomer. Assuming 337 
the same elution order of MDMA enantiomers for HMA and HMMA under the same 338 
chromatographic conditions, the second-eluting enantiomer could be assigned as S-(+)-339 
enantiomer. The expected EFww would then be >0.5 for HMMA. Therefore, we hypothesize 340 
that, if an enrichment of R-(-)-MDMA occurred in the case of consumption, the presence of S-341 
(+)-HMMA would be observable along with an EF>0.5. Consumption estimates from 342 
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wastewater analysis were calculated taking into consideration the following DTRs: MDMA 343 
itself (CF applied was 1.5 as it was widely used in literature (Zuccato, Chiabrando et al. 2008, 344 
Postigo, Lopez de Alda et al. 2010, Nefau, Karolak et al. 2013) even though a new CF of 6.7 345 
was proposed in this study as a result of the most recent excretion data), MDA, HMMA and 346 
HMA (see CF in Table S9S10). The estimates obtained with MDA and HMA showed that these 347 
compounds were not suitable as biomarkers of MDMA consumption. Indeed, the estimates 348 
calculated by using HMMA were quite superimposable to the parent drug MDMA, except for 349 
Oslo. 350 
3.3.Mephedrone 351 
Mephedrone was previously detected in the UK (Castrignanò, Lubben et al. 2016), Italy 352 
(González-Mariño, Gracia-Lor et al. 2016), other European cities (Bade, Bijlsma et al. 2017) 353 
and in China (Khan, van Nuijs et al. 2014). Its occurrence in wastewater can be only ascribed 354 
to illegal disposal or consumption as there is no medical use in Europe (EMCDDA 2011). In 355 
this study, a new CF value has been proposed for the first time to allow for the estimation of 356 
mephedrone use via WBE. Considering urinary excretion of 15.4%±8.4% as unchanged 357 
mephedrone after an oral dose of 150 mg (n=6) (Olesti, Pujadas et al. 2017), CF was set at 6.5. 358 
Population-normalised loads ranged throughout a sampling week from 14.9 to 47.7 mg 1000 359 
people-1 day-1 in the UK (Figures 3 and S2, estimated consumption in Table S16S17). Increasing 360 
loads were found in weekend days rather than weekdays with a mean value of 25.6 ± 12.0 mg 361 
1000 people-1 day-1. A similar trend was observed by Castrignanò et al. (Castrignanò, Lubben 362 
et al. 2016), classifying mephedrone as a recreational drug like MDMA. Furthermore, 363 
mephedrone was found to be enriched with the R-(+)-enantiomer in wastewater (EFww in 2014 364 
(n=6)=0.57±0.02 and EFww in 2015 (n=4)=0.57±0.04). This indicates that mephedrone was consumed 365 
rather than directly disposed (Castrignanò, Mardal et al. 2017, Castrignanò E. 2017 (submitted)) 366 
(see section S4 for further information). 367 
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3.4.Other drugs and precursors 368 
The analysis of drug precursors, such as norephedrine, ephedrine and pseudoephedrine (referred 369 
in the text as ephedrines), was performed only for Oslo, Bristol, Utrecht (only norephedrine) 370 
and Milan (see section S5 for further information). 371 
Mean population-normalised norephedrine loads were 51 mg 1000 people-1 day-1 in Oslo 372 
(probably linked to methamphetamine’s metabolism), 7.1 mg 1000 people-1 day-1 in Milan and 373 
3.4 mg 1000 people-1 day-1 in Bristol (Table S17S18-Figure 4c). Norephedrine was not detected 374 
in wastewater from Utrecht. EFs were 0.48±0.04, 0.56±0.11 and 1.00±0.00 (due to <MQL 375 
values for the first eluting enantiomer), respectively.  376 
Only two stereoisomers of ephedrine were found in European wastewaters: 1R,2S-(-)-ephedrine 377 
and 1S,2S-(+)-pseudoephedrine. Population-normalised 1R,2S-(-)-ephedrine loads were 0.7 mg 378 
1000 people-1 day-1 in Oslo, 3.4 mg 1000 people-1 day-1 in Milan and 0.6 mg 1000 people-1 day-379 
1 in Bristol (Table S18S19-Figure 4a). Mean population-normalised 1S,2S-(+)-pseudoephedrine 380 
loads were 21.2 mg 1000 people-1 day-1 in Oslo, 35.7 mg 1000 people-1 day-1 in Milan and 96.4 381 
mg 1000 people-1 day-1 in Bristol (Table S18S19-Figure 4b). 382 
Chiral PMA (para-methoxyamphetamine), a phenylisopropylamine with hallucinogenic 383 
properties, has no legitimate therapeutical use. It is abused alone or in combination with MDMA 384 
or PMMA. Seizures have been reported in several European countries, including Belgium, 385 
Denmark, Spain, the Netherlands and the UK. However, it was not found in wastewater from 386 
any studied city. This is also in accordance with Kinyua et al. (Kinyua, Covaci et al. 2015). 387 
3.5.Consumption estimates of (meth)amphetamine and ephedrines corrected for legal use: 388 
a case study in England 389 
In England, legal amphetamine prescriptions in 2015 were as follows: 17.8 kg/year of S-(+)-390 
amphetamine (73.4% correction from 23.7 kg/year as dexamfetamine sulphate (Team, Centre 391 
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et al. 2016) to the free base) and 20.3 kg/year as S-(+)-amphetamine (29.7% correction from 392 
68.4 kg/year as lisdexamfetamine dimesylate (Team, Centre et al. 2016) to the free base) (Table 393 
1). Taking into account urinary excretion, the annual amount excreted as S-(+)-amphetamine is 394 
calculated as 5.2 kg from dexamfetamine sulphate consumption and 8.4 kg from 395 
lisdexamfetamine dimesylate. Moreover, 1.3 kg of R-(-)-amphetamine was excreted in 2015 396 
from 9.7 kg/year of prescribed selegiline (Team, Centre et al. 2016). As a result, the contribution 397 
of legal prescribed and excreted amphetamine to wastewater in the WWTP considered in the 398 
study was 1.6 and 0.10 mg day-1 1000 people-1 of S-(+)- and R-(-)-amphetamine, respectively 399 
(this does not consider legally purchased drugs traded illegally). Consumption estimates from 400 
wastewater analysis were back-calculated by using amphetamine and norephedrine as DTRs 401 
(3.3 and 44.7 as corresponding CFs). Despite the good agreement between estimates obtained 402 
with considered DTRs, norephedrine is not recommended as a biomarker for amphetamine use 403 
as it can result from other sources (e.g. disposal of norephedrine and metabolism of ephedrine 404 
and methamphetamine). In relation to these findings, the presence of amphetamine in Bristol 405 
was linked to an illegal use of the substance since the contribution of estimates from the legal 406 
sources was negligible (Table 1). 407 
Regarding methamphetamine, 2.7 kg/year of the R-(-)-enantiomer was excreted into wastewater 408 
as a result of 9.7 kg/year of selegiline intake (Team, Centre et al. 2016). Thus, by normalising 409 
the data with the population equivalent served by the local WWTP in England, 0.18 mg day-1 410 
1000 people-1 of R-(-)-methamphetamine (originating from selegiline consumption) was 411 
estimated in the studied location. Consumption estimates were performed considering 412 
methamphetamine itself, amphetamine and norephedrine as DTRs (see CFs in Table S9S10). 413 
The estimates obtained with amphetamine and norephedrine as DTR were 100-fold higher than 414 
the estimate calculated from methamphetamine. 2.70 mg day-1 1000 people-1 of (±)-415 
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methamphetamine, of which 1.8 as R-(-)-enantiomer, were estimated by using 416 
methamphetamine as DTR, suggesting that its presence was associated mainly with illegal use. 417 
The estimates of the legal use of ephedrines in England in 2015 are as follows (Table 1): 418 
- ephedrine: 0.83 kg/year as hydrochloride (or 0.62 kg/year as free base) resulting in 419 
annual excretion of 0.46 kg of ephedrine in England; 420 
- pseudoephedrine: 253.54 kg/year as hydrochloride (or 223.12 kg/year as 1S,2S-(+)-421 
enantiomer) resulting in annual excretion of 196.34 kg of 1S,2S-(+)-pseudoephedrine in 422 
England; 423 
- norephedrine: 0.35/year and 0.02 kg/year excreted as a result of dexamfetamine sulphate 424 
and ephedrine consumption, respectively. 425 
Furthermore, the metabolism of selegiline produces 0.62% (n=4) of (1S,2R)-(+)-ephedrine, 426 
0.04% (n=4) as (1R,2R)-(-)-pseudoephedrine and 0.12% (n=4) as (1S,2R)-(+)-norephedrine 427 
(Shin 1997). In 2015 in England, 0.06 kg/year of (1S,2R)-(+)-ephedrine, 0.004 kg/year of 428 
(1R,2R)-(-)-pseudoephedrine and 0.011 kg/year as (1S,2R)-(+)-norephedrine were excreted as 429 
a result of 9.72 kg/year of selegiline intake (Team, Centre et al. 2016).  430 
Final estimates, normalised with local WWTP, were 0.034, 10.61 and 0.02 mg day-1 1000 431 
people-1 of ephedrine, pseudoephedrine and norephedrine respectively (CFs in Table S9S10). 432 
For Bristol, consumption estimates were in agreement with the legal usage of ephedrine when 433 
ephedrine itself was used as DTR and discordant in the case of pseudoephedrine and 434 
norephedrine (most likely due to their availability on the OTC market). 435 
 436 
4. Conclusions 437 
This study was the first to spatially and temporally assess the enantiomeric profiling of chiral 438 
illicit drugs in wastewater serving 4.9 million people in eight European cities. Spatial variations 439 
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in drug loads were observed across Europe with higher use of amphetamine in Northern 440 
European cities, revealing a general enrichment of R-(-)-amphetamine in wastewater. The chiral 441 
signature of amphetamine revealed that it is present in wastewater as a result of its consumption. 442 
High methamphetamine loads were detected in Oslo, where racemic methamphetamine was 443 
present, likely due to different trafficking routes from the Baltic countries, rather than Western 444 
and Central Europe. The more potent S-(+)-methamphetamine was the predominant enantiomer 445 
found in wastewater from the other European cities tested, which indicates distribution of 446 
enantiopure S-(+)-methamphetamine on the illicit market. It could suggest that direct 447 
comparison of methamphetamine loads in Oslo and the other European cities should not be 448 
undertaken without considering its chiral signature and the different potency of individual 449 
enantiomers. The analysis of precursors was compatibly ascribed to their medical use. MDMA 450 
was commonly enriched with R-(-)-enantiomer in studied European cities, which indicates 451 
consumption rather than disposal of the unused drug. MDA was commonly found to be enriched 452 
with S-(+)-enantiomer, which indicates that its presence in European wastewaters originates 453 
from MDMA metabolism (especially during weekends) rather than consumption of MDA itself. 454 
However, on a few occasions (UK and The Netherlands), MDA was found to be enriched with 455 
R-(-)-enantiomer, which indicates its consumption. As MDA is a minor metabolite of MDMA, 456 
other metabolites were considered as possible MDMA DTRs, namely HMA and HMMA. 457 
HMMA was found to be a suitable MDMA DTR. Furthermore, its chiral signature indicated its 458 
enrichment with S-(+)-enantiomer, which confirms its origin from MDMA metabolism. 459 
Population-normalised mephedrone loads were up to 47.7 mg 1000 people-1 day-1 in wastewater 460 
in the UK, where an enrichment of R-(+)-enantiomer suggested stereoselective metabolism in 461 
humans, indicating consumption rather than direct disposal.  462 
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